ClinicalTrials.gg
CompletedNCT00593606Updated Oct 2, 2014Results posted

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

A Phase 3 interventional study of Rotigotine in Parkinson's Disease, sponsored by UCB Pharma. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
124
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
21st of 42
124 · median 123
Started
2007
with 5 others
Phase 3
20 of 44
none open now
Registered
14th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 21st largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 20 in phase 3, and was the 14th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

This is a Phase 3b, open-label, multicenter trial to assess the safety and tolerability of switching from ropinirole therapy to the rotigotine transdermal system and its effect on symptoms in subjects with idiopathic Parkinson's disease

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • NEUPRO
  • Switching trial from ropinirole to rotigotine,
  • safety and tolerability
  • Parkinson disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is informed and given ample time and opportunity to think about his/her participation in this trial and has given his/her written .
  • Subject is willing and able to comply with all trial requirements.
  • Subject is male or female, aged≥ 18 years.
  • Subject is Korean.
  • Subjects with idiopathic Parkinson's disease (Hoehn and Yahr Stage I-IV) as defined by the cardinal sign, bradykinesia, and at least 1 of the following: resting tremor, rigidity, or impairment of postural reflexes.
  • Subject is not satisfactorily controlled on a total daily dose of ropinirole from 3mg to 12mg, inclusive.
  • If the subject is receiving levodopa, either short-acting or sustained-release (in combination with benserazide or carbidopa), the total daily dose must be stable for 28 days prior to the Baseline Visit and must remain stable for the Treatment Period.
  • If the subject is receiving an anticholinergic agent (eg, benztropine, trihexyphenidyl, parsitan, procyclidine, biperiden), a monoamine oxidase B (MAO-B) inhibitor (eg, selegiline), a COMT inhibitor (eg, entacapone), or an N-methyl-d-aspartate (NMDA)-antagonist (eg, amantadine), he/she must have been on a stable dose for at least 28 days prior to the Baseline Visit and must be maintained on that dose for the Treatment Period

Exclusion criteria

Exclusion Criteria:

Subjects are not permitted to enroll in the trial if any of the following criteria are met:

  • Subject has previously participated in a trial with rotigotine.
  • Subject has participated in another trial of an drug within 28 days prior to the Baseline Visit or is currently participating in another trial of an investigational drug.
  • Subject has atypical Parkinsonian syndrome(s), including drug-induced Parkinsonian syndrome(s).
  • Subject has dementia, active psychosis, or hallucinations (not due to antiparkinsonian medication).
  • Subject is receiving therapy with 1 of the following drugs either concurrently or within 28 days prior to Baseline Visit: alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, quetiapine), monoamine oxidase A (MAO-A) inhibitors, methylphenidate, or amphetamine.
  • Subject is currently receiving central nervous system (CNS) active therapy (eg, sedatives, hypnotics, antidepressants, anxiolytics), unless the dose has been stable for at least 28 days prior to the Baseline Visit and is likely to remain stable for the duration of the trial.
  • Subject has a history of seizures or stroke within 1 year, has had a (TIA) within 12 months prior to enrollment, or a history of myocardial infarction within the last 6 months prior to enrollment.
  • Presence of hepatic dysfunction.
  • Presence of clinically relevant renal dysfunction.
  • Evidence of clinically relevant cardiovascular disorders.
  • Subject has a interval of ≥ 500ms at Pretreatment or Baseline (repeated measurements within 1 hour).
  • Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension in the 6 months prior to Baseline.
  • Subject has a history of significant skin to adhesive or other transdermals or recent unresolved contact dermatitis.
  • Subject has malignant neoplastic disease requiring therapy within 12 months prior to enrollment.
  • Subject has a history of chronic alcohol or drug abuse within the last 6 months.
  • Subject has taken herbal medicine therapy within the last 2 weeks prior to the Baseline Visit.
  • Subject has clinically significant laboratory results that, in the judgment of the investigator, would make the subject unsuitable for entry into the trial.
  • Subject is pregnant or nursing, or is of but (i) not surgically sterile or (ii) not using adequate methods (including at least 1 barrier method), or (iii) not sexually abstinent or (iv) not at least 2 years .
  • Subject has evidence of an impulse control disorder according to the Jay Modified Minnesota Impulsive Disorders Interview (mMIDI) at Pretreatment (Visit 1).
  • Subject has any other clinically significant medical or psychiatric condition that would, in the judgment of the investigator, interfere with the subject's ability to participate in this trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.

    Drug: Rotigotine

Interventions

  • Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application

    Also known as: Neupro

06

What researchers measure

Primary outcomes

  1. Change in Pulse Rate (Supine, After 1 Minute)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  2. Change in Systolic Blood Pressure (Supine, After 1 Minute)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  3. Change in Diastolic Blood Pressure (Supine, After 1 Minute)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  4. Change in Pulse Rate (Supine, After 5 Minutes)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  5. Change in Systolic Blood Pressure (Supine, After 5 Minutes)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 Days

  6. Change in Diastolic Blood Pressure (Supine, After 5 Minutes)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  7. Change in Pulse Rate (Standing, After 1 Minute)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  8. Change in Systolic Blood Pressure (Standing, After 1 Minute)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  9. Change in Diastolic Blood Pressure (Standing, After 1 Minute)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  10. Change in Pulse Rate (Standing, After 3 Minutes)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  11. Change in Systolic Blood Pressure (Standing, After 3 Minutes)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  12. Change in Diastolic Blood Pressure (Standing, After 3 Minutes)

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  13. Change in Heart Rate

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  14. Change in PR Interval

    The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization (beginning of the QRS complex). Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  15. Change in QRS Duration

    The QRS duration represents the time it takes for ventricular depolarization to occur. Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  16. Change in QT Interval

    The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  17. Change in QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB)

    The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  18. Change in Percentage of Basophilic Granulocytes in White Blood Cell Count

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  19. Change in Percentage of Eosinophilic Granulocytes in White Blood Cell Count

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  20. Change in Hematocrit

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  21. Change in Hemoglobin

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  22. Change in Percentage of Lymphocytes in White Blood Cell Count

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  23. Change in Percentage of Monocytes in White Blood Cell Count

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  24. Change in Percentage of Neutrophilic Granulocytes Segmented in White Blood Cell Count

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  25. Change in Platelet Count

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  26. Change in Red Blood Cell Count

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  27. Change in White Blood Cell Count

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  28. Change in Albumin

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  29. Change in Alkaline Phosphatase

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  30. Change in Blood Urea Nitrogen

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  31. Change in Calcium

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  32. Change in Chloride

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  33. Change in Creatinine

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  34. Change in Gamma-Glutamyltransferase

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  35. Change in Glucose

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  36. Change in Inorganic Phosphate

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  37. Change in Potassium

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  38. Change in Serum Glutamic Oxaloacetic Transaminase

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  39. Change in Glutamic Pyruvic Transaminase

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  40. Change in Sodium

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  41. Change in Total Bilirubin

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  42. Change in Total Protein

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  43. Change in Uric Acid

    Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  44. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Ears, Eyes, Nose, Mouth, Throat'

    Time frame: 28 days

  45. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Psychiatric'

    Time frame: 28 days

  46. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hematological/Lymphatic Nodes'

    Time frame: 28 days

  47. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Dermatological'

    Time frame: 28 days

  48. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Cardiovascular'

    Time frame: 28 days

  49. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Peripheral Vascular'

    Time frame: 28 days

  50. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Pulmonary'

    Time frame: 28 days

  51. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Musculoskeletal'

    Time frame: 28 days

  52. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hepato-/Gastrointestinal'

    Time frame: 28 days

  53. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Renal/Genitourological'

    Time frame: 28 days

  54. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Metabolic/Endocrine'

    Time frame: 28 days

  55. Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Other'

    Time frame: 28 days

  56. Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Mental Status'

    Time frame: 28 days

  57. Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Deep Tendon Reflexes'

    Time frame: 28 days

  58. Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Muscle Strength'

    Time frame: 28 days

  59. Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Cranial Nerve Function'

    Time frame: 28 days

  60. Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Plantar Reflex'

    Time frame: 28 days

  61. Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Gait'

    Time frame: 28 days

  62. Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Coordination/Balance'

    Time frame: 28 days

  63. Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Involuntary Movements'

    Time frame: 28 days

  64. Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Sensory Perception'

    Time frame: 28 days

  65. Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Other'

    Time frame: 28 days

  66. Completion of Trial From Baseline to End of Treatment

    Time frame: Baseline, 28 days

  67. Completion of Trial on the Original Treatment Assignment From Baseline to End of Treatment

    Time frame: Baseline, 28 days

  68. Drop-out During the 5 Half-life Overlap Period Due to Adverse Events (AEs)

    Time frame: Baseline, 2 days

  69. Drop-out Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period

    Time frame: Baseline, 56 days

  70. Dose Reduction During the 5 Half-life Overlap Period Due to Adverse Events (AEs)

    Time frame: Baseline, 2 days

  71. Dose Reduction Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period

    Time frame: Baseline, 56 days

Secondary outcomes

  1. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score From Baseline to End of Treatment

    The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part I measures 'Mentation, Behavior and Mood'. Range: 0 (Best score possible) to 16 (Worst score possible) Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  2. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score From Baseline to End of Treatment

    The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part II measures 'Activities in Daily Living'. Range: 0 (Best score possible) to 52 (Worst score possible) Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  3. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment

    The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part III measures 'Motor Examination'. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  4. Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score From Baseline to End of Treatment

    The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part IV measures 'Complications of Therapy'. Range: 0 (Best score possible) to 23 (Worst score possible) Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  5. Change in Parkinson's Disease Sleep Scale (PDSS) Sum Score From Baseline to End of Treatment

    The PDSS is a scale to assess sleep and nocturnal disability in Parkinson's disease. Range: 0 (Best score possible) to 60 (Worst score possible) Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  6. Change in Epworth Sleepiness Scale (ESS) Sum Score From Baseline to End of Treatment

    The ESS is a self-administered questionnaire in which the subject rates the probability of his/her dozing during 8 situations that are differently conductive to sleep Range: 0 (Best score possible) to 24 (Worst score possible) Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  7. Change in Parkinson's Disease Non-Motor Symptom Assessment Scale (PDNMS) Total Sum Score From Baseline to End of Treatment

    The PDNMS is a rating by the clinician to assess the severity and frequency of non-motor symptoms in Parkinson's disease patients Range: 0 (Best score possible) to 384 (Worst score possible) Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  8. Change in Clinical Global Impression (CGI) Item 1 Score From Baseline to End of Treatment

    The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 1 measures 'Severity of Parkinson's Disease'. Range: 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients) Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  9. Clinical Global Impression (CGI) Item 2 Score

    The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 2 measures 'Global Improvement'. Range 1 (Very much improved) to 7 (Very much worse)

    Time frame: 28 days

  10. Clinical Global Impression (CGI) Item 3.1

    The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3.1 measures 'Therapeutic Effect'. Range: 1 (Marked - Vast improvement. Complete or nearly complete remission of all symptoms.) to 4 (Unchanged or worse)

    Time frame: 28 days

  11. Clinical Global Impression (CGI) Item 3.2

    The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3.2 measures 'Therapeutic Side Effects'. Range: 1 (None) to 4 (Outweigh the therapeutic effect)

    Time frame: 28 days

  12. Patient Global Impression (PGI) Item 1 Score

    The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 1 measures 'Global Improvement'. Range: 1 (Very much improved) to 7 (Very much worse)

    Time frame: 28 days

  13. Patient Global Impression (PGI) Item 2

    The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 2 measures 'Therapeutic Effect'. Range: 1 (Marked - Vast improvement. Complete or nearly complete remission of all symptoms) to 4 (Unchanged or worse)

    Time frame: 28 days

  14. Patient Global Impression (PGI) Item 3

    The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3 measures 'Side Effects'. Range: 1 (I have no side effects) to 4 (They outweigh the therapeutic effect of the trial medication)

    Time frame: 28 days

  15. Change in Short-form Parkinson's Disease Questionnaire (PDQ-8) Single Index Score From Baseline to End of Treatment

    The PDQ-8 is a self-administered 8-item questionnaire that assesses issues associated with Parkinson's disease. Range: 0 (good health) to 100 (poor health) Change = 28 day value minus baseline value.

    Time frame: Baseline, 28 days

  16. Patient Treatment Preference Scale Question 1

    Have you used pharmaceutical treatments for your Parkinson's disease before the study?

    Time frame: 28 days

  17. Patient Treatment Preference Scale Question 2

    Why did you decide to enter this study?

    Time frame: 28 days

  18. Patient Treatment Preference Scale Question 3

    In comparing the patch and previous oral treatments for Parkinson's disease, how satisfied have you been with oral medication / patch?

    Time frame: 28 days

  19. Patient Treatment Preference Scale Question 4

    I would prefer using a patch over taking a pill or capsule for treatment of my Parkinson's disease.

    Time frame: 28 days

  20. Patient Treatment Preference Scale Question 5

    I would prefer applying one 40cm\*\*2 patch over applying two 20cm\*\*2 patches for treatment of my Parkinson's disease.

    Time frame: 28 days

  21. Patient Treatment Preference Scale Question 6

    What aspects do you like the most about the patch?

    Time frame: 28 days

  22. Patient Treatment Preference Scale Question 7

    What aspects do you like the least about the patch? Check all that apply.

    Time frame: 28 days

07

Results

Posted May 27, 2009

Participant flow

124 patients were screened. 5 patients were run-in failures and 3 patients were screen failures. 116 patients started treatment, i.e. were included into the Safety Set. 114 patients were included into the Full Analysis Set. 99 patients completed the treatment period. 2 patients withdrew after the treatment period. 97 patients completed the study.

Participant flow — Overall Study
MilestoneRotigotine
Started124
Start of treatment - safety set116
Full analysis set114
Treatment period completed99
Completed97
Not completed27
Withdrew: Adverse event13
Withdrew: Withdrawal by subject1
Withdrew: Protocol violation3
Withdrew: Lost to follow-up2
Withdrew: Run-in failure5
Withdrew: Screen failure3

Outcome measures

PrimaryChange in Pulse Rate (Supine, After 1 Minute)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · beats per minute
Change in Pulse Rate (Supine, After 1 Minute)
beats per minuteRotigotine
Change in Pulse Rate (Supine, After 1 Minute)2.0 ± 9.4
PrimaryChange in Systolic Blood Pressure (Supine, After 1 Minute)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure (Supine, After 1 Minute)
mmHgRotigotine
Change in Systolic Blood Pressure (Supine, After 1 Minute)5.7 ± 14.1
PrimaryChange in Diastolic Blood Pressure (Supine, After 1 Minute)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure (Supine, After 1 Minute)
mmHgRotigotine
Change in Diastolic Blood Pressure (Supine, After 1 Minute)1.7 ± 9.6
PrimaryChange in Pulse Rate (Supine, After 5 Minutes)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · beats per minute
Change in Pulse Rate (Supine, After 5 Minutes)
beats per minuteRotigotine
Change in Pulse Rate (Supine, After 5 Minutes)1.8 ± 8.8
PrimaryChange in Systolic Blood Pressure (Supine, After 5 Minutes)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 Days
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure (Supine, After 5 Minutes)
mmHgRotigotine
Change in Systolic Blood Pressure (Supine, After 5 Minutes)2.6 ± 13.1
PrimaryChange in Diastolic Blood Pressure (Supine, After 5 Minutes)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure (Supine, After 5 Minutes)
mmHgRotigotine
Change in Diastolic Blood Pressure (Supine, After 5 Minutes)0.6 ± 9.8
PrimaryChange in Pulse Rate (Standing, After 1 Minute)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · beats per minute
Change in Pulse Rate (Standing, After 1 Minute)
beats per minuteRotigotine
Change in Pulse Rate (Standing, After 1 Minute)1.7 ± 11.8
PrimaryChange in Systolic Blood Pressure (Standing, After 1 Minute)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure (Standing, After 1 Minute)
mmHgRotigotine
Change in Systolic Blood Pressure (Standing, After 1 Minute)-0.2 ± 12.7
PrimaryChange in Diastolic Blood Pressure (Standing, After 1 Minute)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure (Standing, After 1 Minute)
mmHgRotigotine
Change in Diastolic Blood Pressure (Standing, After 1 Minute)0.8 ± 10.1
PrimaryChange in Pulse Rate (Standing, After 3 Minutes)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · beats per minute
Change in Pulse Rate (Standing, After 3 Minutes)
beats per minuteRotigotine
Change in Pulse Rate (Standing, After 3 Minutes)0.8 ± 11.1
PrimaryChange in Systolic Blood Pressure (Standing, After 3 Minutes)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure (Standing, After 3 Minutes)
mmHgRotigotine
Change in Systolic Blood Pressure (Standing, After 3 Minutes)2.0 ± 12.4
PrimaryChange in Diastolic Blood Pressure (Standing, After 3 Minutes)

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure (Standing, After 3 Minutes)
mmHgRotigotine
Change in Diastolic Blood Pressure (Standing, After 3 Minutes)0.8 ± 9.1
PrimaryChange in Heart Rate

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · beats per minute
Change in Heart Rate
beats per minuteRotigotine
Change in Heart Rate0.5 ± 8.7
PrimaryChange in PR Interval

The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization (beginning of the QRS complex). Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · msec
Change in PR Interval
msecRotigotine
Change in PR Interval-0.0 ± 14.6
PrimaryChange in QRS Duration

The QRS duration represents the time it takes for ventricular depolarization to occur. Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · msec
Change in QRS Duration
msecRotigotine
Change in QRS Duration-1.2 ± 6.3
PrimaryChange in QT Interval

The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · msec
Change in QT Interval
msecRotigotine
Change in QT Interval-1.7 ± 30.5
PrimaryChange in QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB)

The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · msec
Change in QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB)
msecRotigotine
Change in QT Interval Corrected for Heart Rate According to Bazett's Formula (QTcB)0.5 ± 23.1
PrimaryChange in Percentage of Basophilic Granulocytes in White Blood Cell Count

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Percentage of white blood cell count
Change in Percentage of Basophilic Granulocytes in White Blood Cell Count
Percentage of white blood cell countRotigotine
Change in Percentage of Basophilic Granulocytes in White Blood Cell Count0.01 ± 0.33
PrimaryChange in Percentage of Eosinophilic Granulocytes in White Blood Cell Count

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Percentage of white blood cell count
Change in Percentage of Eosinophilic Granulocytes in White Blood Cell Count
Percentage of white blood cell countRotigotine
Change in Percentage of Eosinophilic Granulocytes in White Blood Cell Count-0.11 ± 1.71
PrimaryChange in Hematocrit

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · l/l*100
Change in Hematocrit
l/l*100Rotigotine
Change in Hematocrit0.09 ± 1.71
PrimaryChange in Hemoglobin

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · g/l
Change in Hemoglobin
g/lRotigotine
Change in Hemoglobin0.8 ± 5.6
PrimaryChange in Percentage of Lymphocytes in White Blood Cell Count

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Percentage of white blood cell count
Change in Percentage of Lymphocytes in White Blood Cell Count
Percentage of white blood cell countRotigotine
Change in Percentage of Lymphocytes in White Blood Cell Count0.73 ± 7.12
PrimaryChange in Percentage of Monocytes in White Blood Cell Count

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Percentage of white blood cell count
Change in Percentage of Monocytes in White Blood Cell Count
Percentage of white blood cell countRotigotine
Change in Percentage of Monocytes in White Blood Cell Count0.96 ± 8.41
PrimaryChange in Percentage of Neutrophilic Granulocytes Segmented in White Blood Cell Count

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Percentage of white blood cell count
Change in Percentage of Neutrophilic Granulocytes Segmented in White Blood Cell Count
Percentage of white blood cell countRotigotine
Change in Percentage of Neutrophilic Granulocytes Segmented in White Blood Cell Count-0.40 ± 12.69
PrimaryChange in Platelet Count

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Giga/l
Change in Platelet Count
Giga/lRotigotine
Change in Platelet Count2.6 ± 29.5
PrimaryChange in Red Blood Cell Count

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Tera/l
Change in Red Blood Cell Count
Tera/lRotigotine
Change in Red Blood Cell Count0.023 ± 0.213
PrimaryChange in White Blood Cell Count

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Giga/l
Change in White Blood Cell Count
Giga/lRotigotine
Change in White Blood Cell Count-0.045 ± 3.538
PrimaryChange in Albumin

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · g/l
Change in Albumin
g/lRotigotine
Change in Albumin-0.5 ± 2.1
PrimaryChange in Alkaline Phosphatase

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Units/l
Change in Alkaline Phosphatase
Units/lRotigotine
Change in Alkaline Phosphatase-1.4 ± 16.9
PrimaryChange in Blood Urea Nitrogen

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmol/l
Change in Blood Urea Nitrogen
mmol/lRotigotine
Change in Blood Urea Nitrogen-0.24 ± 1.75
PrimaryChange in Calcium

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mg/dl
Change in Calcium
mg/dlRotigotine
Change in Calcium-0.05 ± 0.30
PrimaryChange in Chloride

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmol/l
Change in Chloride
mmol/lRotigotine
Change in Chloride-0.4 ± 2.5
PrimaryChange in Creatinine

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mg/dl
Change in Creatinine
mg/dlRotigotine
Change in Creatinine-0.004 ± 0.101
PrimaryChange in Gamma-Glutamyltransferase

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Units/l
Change in Gamma-Glutamyltransferase
Units/lRotigotine
Change in Gamma-Glutamyltransferase-0.1 ± 7.5
PrimaryChange in Glucose

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mg/dl
Change in Glucose
mg/dlRotigotine
Change in Glucose-0.2 ± 30.0
PrimaryChange in Inorganic Phosphate

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mg/dl
Change in Inorganic Phosphate
mg/dlRotigotine
Change in Inorganic Phosphate-0.03 ± 0.52
PrimaryChange in Potassium

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmol/l
Change in Potassium
mmol/lRotigotine
Change in Potassium0.08 ± 0.35
PrimaryChange in Serum Glutamic Oxaloacetic Transaminase

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Units/l
Change in Serum Glutamic Oxaloacetic Transaminase
Units/lRotigotine
Change in Serum Glutamic Oxaloacetic Transaminase-0.1 ± 7.9
PrimaryChange in Glutamic Pyruvic Transaminase

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · Units/l
Change in Glutamic Pyruvic Transaminase
Units/lRotigotine
Change in Glutamic Pyruvic Transaminase-0.2 ± 15.6
PrimaryChange in Sodium

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mmol/l
Change in Sodium
mmol/lRotigotine
Change in Sodium-0.6 ± 2.2
PrimaryChange in Total Bilirubin

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · mg/dl
Change in Total Bilirubin
mg/dlRotigotine
Change in Total Bilirubin0.079 ± 1.133
PrimaryChange in Total Protein

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · g/dl
Change in Total Protein
g/dlRotigotine
Change in Total Protein-0.09 ± 0.36
PrimaryChange in Uric Acid

Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · µmol/l
Change in Uric Acid
µmol/lRotigotine
Change in Uric Acid-3.80 ± 35.62
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Ears, Eyes, Nose, Mouth, Throat'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Ears, Eyes, Nose, Mouth, Throat'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Ears, Eyes, Nose, Mouth, Throat'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Psychiatric'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Psychiatric'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Psychiatric'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hematological/Lymphatic Nodes'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hematological/Lymphatic Nodes'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hematological/Lymphatic Nodes'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Dermatological'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Dermatological'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Dermatological'1
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Cardiovascular'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Cardiovascular'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Cardiovascular'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Peripheral Vascular'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Peripheral Vascular'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Peripheral Vascular'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Pulmonary'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Pulmonary'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Pulmonary'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Musculoskeletal'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Musculoskeletal'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Musculoskeletal'1
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hepato-/Gastrointestinal'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hepato-/Gastrointestinal'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Hepato-/Gastrointestinal'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Renal/Genitourological'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Renal/Genitourological'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Renal/Genitourological'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Metabolic/Endocrine'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Metabolic/Endocrine'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Metabolic/Endocrine'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Other'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Other'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Physical Examination for 'Other'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Mental Status'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Mental Status'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Mental Status'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Deep Tendon Reflexes'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Deep Tendon Reflexes'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Deep Tendon Reflexes'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Muscle Strength'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Muscle Strength'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Muscle Strength'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Cranial Nerve Function'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Cranial Nerve Function'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Cranial Nerve Function'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Plantar Reflex'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Plantar Reflex'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Plantar Reflex'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Gait'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Gait'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Gait'1
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Coordination/Balance'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Coordination/Balance'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Coordination/Balance'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Involuntary Movements'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Involuntary Movements'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Involuntary Movements'1
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Sensory Perception'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Sensory Perception'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Sensory Perception'0
PrimaryOccurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Other'
Time frame:
28 days
Reported as:
Number · participants
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Other'
participantsRotigotine
Occurrence of Abnormal, Clinically Relevant Events in Neurological Examination for 'Other'0
PrimaryCompletion of Trial From Baseline to End of Treatment
Time frame:
Baseline, 28 days
Reported as:
Number · participants
Completion of Trial From Baseline to End of Treatment
participantsRotigotine
Completion of Trial From Baseline to End of Treatment99
PrimaryCompletion of Trial on the Original Treatment Assignment From Baseline to End of Treatment
Time frame:
Baseline, 28 days
Reported as:
Number · participants
Completion of Trial on the Original Treatment Assignment From Baseline to End of Treatment
participantsRotigotine
Completion of Trial on the Original Treatment Assignment From Baseline to End of Treatment88
PrimaryDrop-out During the 5 Half-life Overlap Period Due to Adverse Events (AEs)
Time frame:
Baseline, 2 days
Reported as:
Number · participants
Drop-out During the 5 Half-life Overlap Period Due to Adverse Events (AEs)
participantsRotigotine
Drop-out During the 5 Half-life Overlap Period Due to Adverse Events (AEs)0
PrimaryDrop-out Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period
Time frame:
Baseline, 56 days
Reported as:
Number · participants
Drop-out Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period
participantsRotigotine
Drop-out Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period9
PrimaryDose Reduction During the 5 Half-life Overlap Period Due to Adverse Events (AEs)
Time frame:
Baseline, 2 days
Reported as:
Number · participants
Dose Reduction During the 5 Half-life Overlap Period Due to Adverse Events (AEs)
participantsRotigotine
Dose Reduction During the 5 Half-life Overlap Period Due to Adverse Events (AEs)1
PrimaryDose Reduction Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period
Time frame:
Baseline, 56 days
Reported as:
Number · participants
Dose Reduction Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period
participantsRotigotine
Dose Reduction Due to Adverse Events (AEs) With Onset During the 5 Half-life Overlap Period1
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score From Baseline to End of Treatment

The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part I measures 'Mentation, Behavior and Mood'. Range: 0 (Best score possible) to 16 (Worst score possible) Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · score on scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score From Baseline to End of Treatment
score on scaleRotigotine
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score From Baseline to End of Treatment-0.5 ± 1.2
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score From Baseline to End of Treatment

The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part II measures 'Activities in Daily Living'. Range: 0 (Best score possible) to 52 (Worst score possible) Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · score on scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score From Baseline to End of Treatment
score on scaleRotigotine
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score From Baseline to End of Treatment-0.9 ± 3.3
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment

The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part III measures 'Motor Examination'. Range: 0 (Best score possible) to 56 (Worst score possible) Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · score on scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment
score on scaleRotigotine
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment-1.9 ± 5.9
SecondaryChange in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score From Baseline to End of Treatment

The UPDRS is a scale for the assessment of function in Parkinson's disease UPDRS Part IV measures 'Complications of Therapy'. Range: 0 (Best score possible) to 23 (Worst score possible) Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · score on scale
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score From Baseline to End of Treatment
score on scaleRotigotine
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score From Baseline to End of Treatment-0.4 ± 1.8
SecondaryChange in Parkinson's Disease Sleep Scale (PDSS) Sum Score From Baseline to End of Treatment

The PDSS is a scale to assess sleep and nocturnal disability in Parkinson's disease. Range: 0 (Best score possible) to 60 (Worst score possible) Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · score on scale
Change in Parkinson's Disease Sleep Scale (PDSS) Sum Score From Baseline to End of Treatment
score on scaleRotigotine
Change in Parkinson's Disease Sleep Scale (PDSS) Sum Score From Baseline to End of Treatment-0.8 ± 7.3
SecondaryChange in Epworth Sleepiness Scale (ESS) Sum Score From Baseline to End of Treatment

The ESS is a self-administered questionnaire in which the subject rates the probability of his/her dozing during 8 situations that are differently conductive to sleep Range: 0 (Best score possible) to 24 (Worst score possible) Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · score on scale
Change in Epworth Sleepiness Scale (ESS) Sum Score From Baseline to End of Treatment
score on scaleRotigotine
Change in Epworth Sleepiness Scale (ESS) Sum Score From Baseline to End of Treatment-0.2 ± 3.2
SecondaryChange in Parkinson's Disease Non-Motor Symptom Assessment Scale (PDNMS) Total Sum Score From Baseline to End of Treatment

The PDNMS is a rating by the clinician to assess the severity and frequency of non-motor symptoms in Parkinson's disease patients Range: 0 (Best score possible) to 384 (Worst score possible) Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · score on scale
Change in Parkinson's Disease Non-Motor Symptom Assessment Scale (PDNMS) Total Sum Score From Baseline to End of Treatment
score on scaleRotigotine
Change in Parkinson's Disease Non-Motor Symptom Assessment Scale (PDNMS) Total Sum Score From Baseline to End of Treatment-7.9 ± 19.8
SecondaryChange in Clinical Global Impression (CGI) Item 1 Score From Baseline to End of Treatment

The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 1 measures 'Severity of Parkinson's Disease'. Range: 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients) Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · score on scale
Change in Clinical Global Impression (CGI) Item 1 Score From Baseline to End of Treatment
score on scaleRotigotine
Change in Clinical Global Impression (CGI) Item 1 Score From Baseline to End of Treatment-0.0 ± 0.6
SecondaryClinical Global Impression (CGI) Item 2 Score

The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 2 measures 'Global Improvement'. Range 1 (Very much improved) to 7 (Very much worse)

Time frame:
28 days
Reported as:
Mean · score on scale
Clinical Global Impression (CGI) Item 2 Score
score on scaleRotigotine
Clinical Global Impression (CGI) Item 2 Score3.6 ± 1.0
SecondaryClinical Global Impression (CGI) Item 3.1

The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3.1 measures 'Therapeutic Effect'. Range: 1 (Marked - Vast improvement. Complete or nearly complete remission of all symptoms.) to 4 (Unchanged or worse)

Time frame:
28 days
Reported as:
Number · participants
Clinical Global Impression (CGI) Item 3.1
participantsRotigotine
Marked3
Moderate20
Minimal36
Unchanged or Worse54
Not Assessed1
SecondaryClinical Global Impression (CGI) Item 3.2

The CGI is a set of ratings made by a clinician in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3.2 measures 'Therapeutic Side Effects'. Range: 1 (None) to 4 (Outweigh the therapeutic effect)

Time frame:
28 days
Reported as:
Number · participants
Clinical Global Impression (CGI) Item 3.2
participantsRotigotine
None88
No Significant Interference with Subj. Functioning18
Significant Interference with Subj. Functioning5
Outweigh the Theraputic Effect2
Not Assessed1
SecondaryPatient Global Impression (PGI) Item 1 Score

The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 1 measures 'Global Improvement'. Range: 1 (Very much improved) to 7 (Very much worse)

Time frame:
28 days
Reported as:
Mean · score on scale
Patient Global Impression (PGI) Item 1 Score
score on scaleRotigotine
Patient Global Impression (PGI) Item 1 Score3.6 ± 1.2
SecondaryPatient Global Impression (PGI) Item 2

The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 2 measures 'Therapeutic Effect'. Range: 1 (Marked - Vast improvement. Complete or nearly complete remission of all symptoms) to 4 (Unchanged or worse)

Time frame:
28 days
Reported as:
Number · participants
Patient Global Impression (PGI) Item 2
participantsRotigotine
Marked5
Moderate25
Minimal38
Unchanged or Worse44
Missing / Not Done2
SecondaryPatient Global Impression (PGI) Item 3

The PGI is a set of ratings made by the patient in order to assess the overall severity of an individual's symptoms as well as changes in his/her functioning over time. Item 3 measures 'Side Effects'. Range: 1 (I have no side effects) to 4 (They outweigh the therapeutic effect of the trial medication)

Time frame:
28 days
Reported as:
Number · participants
Patient Global Impression (PGI) Item 3
participantsRotigotine
No Side Effects77
No Significant Interference with Functioning24
Significant Interference with Functioning6
Outweighing Therapeutic Effect of Trial Medication5
Missing / Not Done2
SecondaryChange in Short-form Parkinson's Disease Questionnaire (PDQ-8) Single Index Score From Baseline to End of Treatment

The PDQ-8 is a self-administered 8-item questionnaire that assesses issues associated with Parkinson's disease. Range: 0 (good health) to 100 (poor health) Change = 28 day value minus baseline value.

Time frame:
Baseline, 28 days
Reported as:
Mean · score on scale
Change in Short-form Parkinson's Disease Questionnaire (PDQ-8) Single Index Score From Baseline to End of Treatment
score on scaleRotigotine
Change in Short-form Parkinson's Disease Questionnaire (PDQ-8) Single Index Score From Baseline to End of Treatment-3.9 ± 13.5
SecondaryPatient Treatment Preference Scale Question 1

Have you used pharmaceutical treatments for your Parkinson's disease before the study?

Time frame:
28 days
Reported as:
Number · participants
Patient Treatment Preference Scale Question 1
participantsRotigotine
yes114
no0
SecondaryPatient Treatment Preference Scale Question 2

Why did you decide to enter this study?

Time frame:
28 days
Reported as:
Number · participants
Patient Treatment Preference Scale Question 2
participantsRotigotine
Side effects with oral medicine14
Oral medicine not effective in controlling sympt.21
Taking med. several times a day was not convenient71
Other40
SecondaryPatient Treatment Preference Scale Question 3

In comparing the patch and previous oral treatments for Parkinson's disease, how satisfied have you been with oral medication / patch?

Time frame:
28 days
Reported as:
Number · participants
Patient Treatment Preference Scale Question 3
participantsRotigotine
Very Dissatisfied with Oral Medication3
Dissatisfied with Oral Medication11
Neither Satisfied nor Dissatisfied with Oral Med.49
Satisfied with Oral Medication43
Very Satisfied with Oral Medication6
Assessment for Oral Medication Missing / Not Done2
Very Dissatisfied with Patch9
Dissatisfied with Patch28
Neither Satisfied nor Dissatisfied with Patch34
Satisfied with Patch32
Very Satisfied with Patch9
Assessment for Patch Missing / Not Done2
SecondaryPatient Treatment Preference Scale Question 4

I would prefer using a patch over taking a pill or capsule for treatment of my Parkinson's disease.

Time frame:
28 days
Reported as:
Number · participants
Patient Treatment Preference Scale Question 4
participantsRotigotine
Strongly Agree18
Agree34
Neither Agree nor Disagree29
Disagree28
Strongly Disagree3
Not Done / Missing2
SecondaryPatient Treatment Preference Scale Question 5

I would prefer applying one 40cm\*\*2 patch over applying two 20cm\*\*2 patches for treatment of my Parkinson's disease.

Time frame:
28 days
Reported as:
Number · participants
Patient Treatment Preference Scale Question 5
participantsRotigotine
Strongly Agree17
Agree68
Neither Agree nor Disagree10
Disagree13
Strongly Disagree4
Not Done / Missing2
SecondaryPatient Treatment Preference Scale Question 6

What aspects do you like the most about the patch?

Time frame:
28 days
Reported as:
Number · participants
Patient Treatment Preference Scale Question 6
participantsRotigotine
Applying the patch once a day81
Comfortable to wear28
Does not interfere with my normal activities61
Do not have to take medicine in public56
Provides symptom relief all day46
Convenient53
Easy to apply50
Do not have to remember to take med. during day60
Missing / Not Done2
SecondaryPatient Treatment Preference Scale Question 7

What aspects do you like the least about the patch? Check all that apply.

Time frame:
28 days
Reported as:
Number · participants
Patient Treatment Preference Scale Question 7
participantsRotigotine
Hard to apply11
Hard to remove3
Hard to remove the patch from its pouch1
Did not stay on for the entire day80
Uncomfortable to wear27
Not always covered by clothing8
Symptom relief did not last all day29
Not Done / Missing2

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—0/116 (0%)45/116 (38.8%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventRotigotine
DizzinessNervous system disorders7/116
TremorNervous system disorders7/116
AstheniaGeneral disorders6/116
DyskinesiaNervous system disorders6/116
Muscle rigidityMusculoskeletal and connective tissue disorders5/116
Dry MouthGastrointestinal disorders4/116
BradykinesiaNervous system disorders4/116
SomnolenceNervous system disorders4/116
Application site pruritusGeneral disorders3/116
DyspepsiaGastrointestinal disorders2/116

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rotigotine
<=18 years0
Between 18 and 65 years73
>=65 years43
Age, Continuous
Age, Continuous(years)Rotigotine
Mean60.0 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female69
Male47
Region of Enrollment
Region of Enrollment(participants)Rotigotine
Korea, Republic of116
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kim HJ, Jeon BS, Lee WY, Lee MC, Kim JW, Kim JM, Ahn TB, Cho J, Chung SJ, Grieger F, Whitesides J, Boroojerdi B. Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease. BMC Neurol. 2011 Aug 10;11:100. doi: 10.1186/1471-2377-11-100. PubMed 21831297 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2007
First posted
Jan 15, 2008
Start
Jul 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
May 27, 2009
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00593606
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jan 15, 2008
Start date
Jul 2007
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
May 27, 2009
Last update
Oct 2, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion